Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug
ZURICH: Novartis said it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.
Novartis, which said the deal includes additional payments, royalties, and fees pending the achievement of milestones, already has a blockbuster drug, Cosentyx, in immunology with accelerating sales in psoriasis and ankylosing spondylitis.
(Reporting by John Miller; Editing by Jan Harvey)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd